Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Cash from Operations (2024 - 2026)

Beta Bionics recorded quarterly Cash from Operations of 23832000.0 in Q1 2026, down 176.25% quarter-over-quarter from 8627000.0 in Q4 2025, and down 19.31% year-over-year from 29534942.3 in Q1 2025.

Beta Bionics' Cash from Operations history runs 3 years deep, the most recent figure standing at 23832000.0 for Q1 2026.

  • In Q1 2026, Cash from Operations fell 19.31% year-over-year to 23832000.0; the TTM figure through Mar 2026 stood at 54782000.0 (up 2.36% YoY), while the FY2025 annual figure was 50925000.0, down 5.49% from the prior year.
  • Cash from Operations came in at 23832000.0 for Q1 2026 at Beta Bionics, down from 8627000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 8627000.0 in Q4 2025 to a low of 23832000.0 in Q1 2026.
  • A 3-year average of 13670000.0 and a median of 12237000.0 in 2024 frame the typical range for Cash from Operations.
  • On a YoY basis, Cash from Operations climbed as much as 39.58% in 2025 and fell as far as 64.48% in 2025.
  • Beta Bionics' Cash from Operations stood at 14279000.0 in 2024, then surged by 39.58% to 8627000.0 in 2025, then tumbled by 176.25% to 23832000.0 in 2026.
  • According to Business Quant data, Cash from Operations over the past three periods registered 23832000.0, 8627000.0, and 8729000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Operations (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 1.32 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 581.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 2.74 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 348.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 43.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 220.10 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 525.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 290.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 335.40 Mn
10 Beta Bionics 572.34 Mn 542.03 Mn 16.44 Mn -23.83 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -23.83 Mn
Mar 31, 2026 -23.83 Mn
Dec 31, 2025 -8.63 Mn
Dec 31, 2025 -8.63 Mn
Sep 30, 2025 -8.73 Mn
Sep 30, 2025 -8.73 Mn
Jun 30, 2025 -13.59 Mn
Jun 30, 2025 -13.59 Mn
Mar 31, 2025 -19.98 Mn
Mar 31, 2025 -19.98 Mn
Dec 31, 2024 -14.28 Mn
Dec 31, 2024 -14.28 Mn
Sep 30, 2024 -9.61 Mn
Sep 30, 2024 -9.61 Mn
Jun 30, 2024 -12.24 Mn
Jun 30, 2024 -12.24 Mn
Mar 31, 2024 -12.14 Mn
Mar 31, 2024 -12.14 Mn